多重抗药性菌之感染控制.pptVIP

下载本文档

1
0
约1.76万字
约 49页
2019-10-17 发布于湖北
举报
版权申诉

多重抗药性菌之感染控制.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Management of ventilator-associated pneumonia Ibrahim EH, et al. Crit care Med 2001;29:1109-15. Comparison of Shorter versus Longer Duration of Therapy for VAP After initiating of guideline: Similar mortality, shorter hospital stay Lower occurrence of secondary VAP Multi-drug resistant pathogen more frequently in patients treated for 15 days For uncertain pathogen of VAP and response to treatment occur within first 6 days ? 7-8 day therapy is sufficient ! Ibrahim EH, et al. Crit care Med 2001;29:1109-15. Rello J, et al. Crit Care Med 2004;32:2183-90. Chastre J, et al. JAMA 2003;290:2588-98. Rotating (cycling) antibiotics Antibiotic Cycling vs. Diversity Cycling (Rotation) Diversity Models and clinical trials shown that heterogeneous antibiotic use is a potential way of reducing the selection pressure that leads to antibiotic resistance Brown EM . J Antimicrob Chemother. 2005;55:6-9. Fridkin SK. Clin Infect Dis. 2003;36:1438-44. Bergstrom CT. Proc Natl Acad Sci USA. 2004;101:13285-90. Bonhoeffer S. Proc Natl Acad Sci USA. 1997;94:12106-11. Bonten MJ. Clin Infect Dis. 2001;33:1739-46. Sandiumenge A. J Antimicrob Chemother. 2006;57:1197-204. Cycling vs. Mixing and Selective Pressure on a Bacterial Clone Bergstrom CT, et al. Proc Natl Acad Sci. 2004;101:13285-13290. Mixing use of antibiotic offers greater heterogeneity Restriction use of 3rd-cephalosporin ESBL-K. pneumoniae outbreak at ICU Associated with 3rd cephem use Restriction use of 3rd ceph., substitute to imipenem Decrease ESBL-KP, but lead to IMP-R Acinetobacter (metallo-b-lactamase) and P. aeruginosa (loss porins) Pena, et al. AAC 1998;42:53-7. Impact of cephalosporin restriction 44% reduction of ESBL K. pneumoniae 68% increased IMP-resistant P. aeruginosa Rahal, et al. JAMA 1998;280:1233-7. Infection Control to Prevent MDR-bacterial infection A. baumannii VRE; MRSA Pseudomonas S. maltoph